State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Sun Yat-sen University, Guangzhou, China.
Ocul Immunol Inflamm. 2024 Oct;32(8):1599-1608. doi: 10.1080/09273948.2023.2266763. Epub 2023 Oct 20.
To evaluate the efficacy and safety of intense pulsed light combined with meibomian gland expression (IPL-MGX) for treating meibomian gland dysfunction (MGD) associated with chronic ocular graft-versus-host disease (oGVHD).
This retrospective study included 18 patients (18 eyes) with Fitzpatrick skin type ≤ IV, who underwent 3 to 8 sessions of IPL-MGX. Dry eye symptomology, ocular surface parameters, and adverse events were evaluated.
Of 18 eyes, 83.3% and 66.7% showed severe oGVHD and severe MGD, respectively. At 4 weeks after the final session, significant improvements in the OSDI ( < 0.001), SPEED ( = 0.001), meibum expressibility ( < 0.001), and meibum quality ( = 0.016) were observed. At 12 weeks after, the OSDI ( = 0.009), SPEED ( = 0.002), and meibum expressibility ( = 0.008) significantly improved. No adverse events owing to IPL were reported.
IPL-MGX may improve the ocular symptoms, ameliorate meibomian gland secretion, and is considered as a safe treatment for MGD in oGVHD patients.
评估强脉冲光联合睑板腺按摩（IPL-MGX）治疗慢性移植物抗宿主病（oGVHD）相关睑板腺功能障碍（MGD）的疗效和安全性。
本回顾性研究纳入了 18 名（18 只眼）Fitzpatrick 皮肤类型≤IV 的患者，他们接受了 3 至 8 次 IPL-MGX 治疗。评估干眼症状、眼表参数和不良反应。
18 只眼中，83.3%和 66.7%分别为严重 oGVHD 和严重 MGD。末次治疗后 4 周，OSDI（<0.001）、SPEED（=0.001）、睑脂排出量（<0.001）和睑脂质量（=0.016）显著改善。12 周后，OSDI（=0.009）、SPEED（=0.002）和睑脂排出量（=0.008）显著改善。未报告因 IPL 引起的不良反应。
IPL-MGX 可能改善眼部症状，改善睑板腺分泌功能，被认为是 oGVHD 患者 MGD 的安全治疗方法。
